Phil, a San Francisco, CA-based software-driven pharmaceutical commercialization platform, obtained $60m development debt financing from K2 HealthVentures (K2HV).
The funding will speed up the mixing of synthetic intelligence throughout Phil’s platform and assist continued buyer growth throughout a broad vary of therapeutic areas.
Led by Deepak Thomas, Founder and CEO, Phil supplies a software-driven remedy deployment platform that permits pharmaceutical producers to ship remedy entry to sufferers by integrating digital stakeholder experiences, affected person entry providers, market entry instruments, and versatile distribution fashions.
Since its Sequence D financing led by Warburg Pincus in 2021, the corporate has scaled prescription volumes greater than 10x, and ended 2024 with over 150% year-over-year web income development whereas producing optimistic working money circulate.
FinSMEs
09/07/2025
